Skip To Main Content
Rachel Sachs on Muck Rack

Rachel Sachs

  • Associate Professor, Washington University in St. Louis School of Law
St. Louis
As seen in: Washington Post Opinions, Oxford University Press (OUP), The Atlantic, Scientific American, The Conversation, Brookings Institution, Chron, JAMA (The Journal of the American Medical Association), JAMA: Journal of the American Medical Association, JAMA Health Forum Conversations and
Professor of Law, Washington University in St. Louis. Researching and writing about innovation policy, mostly in health law, FDA law, and patent law.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rachel

Contact Rachel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

CMS’ GLP-1 Bridge Demonstration—Questions and Potential Consequences

|
By Rachel Sachs, Kristi Martin
| JAMA: Journal of the American Medical Association Verified
In April 2026, the US Centers for Medicare & Medicaid Services (CMS) announced the agency’s proposed Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model, which sought voluntary participation from Medicare Part D plans in expanding access to branded antiobesity medications (particularly glucagon-like peptide-1 [GLP-1] agonists), would be delayed due to lack of plan participation.
Open in Who Shared Issue with article?

Biosimilar Competition in Oncology—Beyond Insurer Pressure

|
By Rachel Sachs
| JAMA: Journal of the American Medical Association Verified
The high price of drugs continues to be the focus of policy discussions, with attention often drawn to the importance of promoting price competition through the use of generic and biosimilar versions of branded reference products.
Open in Who Shared Issue with article?

Comments on GLOBE and GUARD drug pricing models

|
By Richard Frank, Kristi Martin, Rachel Sachs
| Brookings Institution
Editor's note: The authors submitted both comment letters to the Centers for Medicare & Medicaid Services on February 23, 2026. Richard G. Frank, Kristi Martin, and Rachel E. Sachs provide the Centers for Medicare & Medicaid Services with comments on the proposed Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model.
Open in Who Shared Issue with article?
See all 60 licensed articles (65 Total)